HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Drop in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,200 shares, a decline of 7.7% from the May 15th total of 1,300 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 17,700 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Avantax Planning Partners Inc. acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 179,541 shares of the company’s stock, valued at approximately $220,000. Avantax Planning Partners Inc. owned 0.50% of HCW Biologics as of its most recent SEC filing. Institutional investors and hedge funds own 2.96% of the company’s stock.

HCW Biologics Stock Performance

Shares of NASDAQ:HCWB remained flat at $1.02 on Tuesday. The stock had a trading volume of 5,303 shares, compared to its average volume of 15,488. The firm has a market capitalization of $38.58 million, a P/E ratio of -1.34 and a beta of 0.93. The business has a 50-day moving average of $1.26 and a 200 day moving average of $1.29. HCW Biologics has a twelve month low of $0.91 and a twelve month high of $2.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.46 and a current ratio of 0.46.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $1.13 million for the quarter. HCW Biologics had a negative return on equity of 146.76% and a negative net margin of 697.53%.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.